One scoping review found an increased level of fecal and urinary markers (macrophage migration inhibitory factor (MIF) and fecal glyceraldehyde) in patients with bladder pain syndrome (BPS). The gene discussed is MIF; the disease is Bartsocas-Papas syndrome 1.